MONTREAL, QUEBEC--(Marketwire - April 15, 2008) - MethylGene Inc. (TSX: MYG) announces that MethylGene and Celgene Corporation intend to advance the development of MGCD0103 during 2008. The companies are working together to advance several MGCD0103 programs including acute myelogenous leukemia, Hodgkin disease, myelodysplastic syndromes and solid tumor cancers following the acquisition of Pharmion Corporation by Celgene. As clinical development strategies and plans are developed between the two companies, updates will be provided as appropriate.
